IPO Stock Arcellx Breaks Out On $325 Million Cancer Deal With Gilead

Recent initial public offering Arcellx (ACLX) forged a $325 million multiple myeloma deal with Gilead Sciences (GILD) on Friday, and the IPO stock broke out. X The news comes in lockstep with promisin...